Clinical and pathologic characteristics of patients with DLBCL biopsies having discordant CD20 or CD5 expression
| Variable . | Discordant CD20, no. (%), n = 35 . | CD5 expression, no. (%), n = 24 . |
|---|---|---|
| Age > 60 y | 22 (63) | 14 (58) |
| Male sex | 26 (74) | 16 (64) |
| PS > 1 | 16 (45) | 11 (46) |
| LDH > normal | 24 (69) | 15 (62) |
| Extranodal sites > 1 | 10 (29) | 6 (25) |
| Stage III/IV | 32 (91) | 14 (60) |
| IPI score at diagnosis | ||
| 0 | 3 (9) | 2 (8) |
| 1, 2 | 9 (26) | 9 (38) |
| 3-5 | 23 (65) | 13 (54) |
| CD5 expression | 11 (31) | 24 (100) |
| Discordant CD20 by FCM | 35 (100) | 13 (54) |
| Bright CD20 expression by IHC | 33 (94) | 24 (100) |
| BCL2 protein expression | 28 (81) | 20 (83) |
| DLBCL subtype (cell of origin) | ||
| GCB | 6 (17) | 5 (21) |
| Non-GCB, ABC, or unclassifiable | 12 (34) | 8 (33) |
| Not available | 17 (49) | 11 (46) |
| Relapse or progression | 22 (63) | 12 (50) |
| Variable . | Discordant CD20, no. (%), n = 35 . | CD5 expression, no. (%), n = 24 . |
|---|---|---|
| Age > 60 y | 22 (63) | 14 (58) |
| Male sex | 26 (74) | 16 (64) |
| PS > 1 | 16 (45) | 11 (46) |
| LDH > normal | 24 (69) | 15 (62) |
| Extranodal sites > 1 | 10 (29) | 6 (25) |
| Stage III/IV | 32 (91) | 14 (60) |
| IPI score at diagnosis | ||
| 0 | 3 (9) | 2 (8) |
| 1, 2 | 9 (26) | 9 (38) |
| 3-5 | 23 (65) | 13 (54) |
| CD5 expression | 11 (31) | 24 (100) |
| Discordant CD20 by FCM | 35 (100) | 13 (54) |
| Bright CD20 expression by IHC | 33 (94) | 24 (100) |
| BCL2 protein expression | 28 (81) | 20 (83) |
| DLBCL subtype (cell of origin) | ||
| GCB | 6 (17) | 5 (21) |
| Non-GCB, ABC, or unclassifiable | 12 (34) | 8 (33) |
| Not available | 17 (49) | 11 (46) |
| Relapse or progression | 22 (63) | 12 (50) |
PS indicates Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; FCM, flow cytometry; IHC, immunohistochemistry; DLBCL, diffuse large B-cell lymphoma; GCB, germinal B-cell type; ABC, activated B-cell type; and Discordant CD20, reduced CD20 but bright CD19 expression by flow cytometry.